OncoGenex Pharmaceuticals plans to price public offering of its shares

Bookrunners Leerink Swann and Stifel Nicolaus Weisel assist with sale

By Devika Patel

Knoxville, Tenn., March 15 - OncoGenex Pharmaceuticals, Inc. will price a public offering of common stock with a 30-day 15% greenshoe option, according to a preliminary prospectus supplement filed Thursday with the Securities and Exchange Commission.

Leerink Swann LLC and Stifel Nicolaus Weisel are the joint bookrunning managers and Lazard Capital Markets LLC and William Blair & Co., LLC are co-managers.

Proceeds will be used to advance the company's proprietary product OGX-427 and its pre-clinical product candidates, as well as for general corporate purposes.

OncoGenex Pharmaceuticals, based in Bothell, Wash., is a biopharmaceutical company engaged in the development and commercialization of cancer therapies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.